3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Plasma cell
1
Dermatologic
1
Conditions
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
32
fludarabine phosphate
25
Peripheral Blood Stem Cell Transplantation
25
Busulfan
20
Antilymphocyte Serum
19
Tacrolimus
15
Mycophenolic Acid
15
Filgrastim
15
Cyclosporine
15
Methotrexate
14
Melphalan
12
Etoposide
12
pembrolizumab
11
Whole-Body Irradiation
10
Radiotherapy
10
Methylprednisolone
10
Sirolimus
9
Psychiatric Rehabilitation
8
Nivolumab
8
Bortezomib
8
fludarabine
7
Prednisone
7
Flow Cytometry
7
sargramostim
6
romidepsin
6
Vorinostat
6
Gemcitabine
6
Doxorubicin
6
Cord Blood Stem Cell Transplantation
6
aldesleukin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
abexinostat
×
Dermatologic
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts